BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 21, 2026
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

Cardiac monitoring meets smartphones with Abbott's latest CE mark approval

May 9, 2017
By Omar Ford

Abiomed enrolls first patient in Impella STEMI feasibility trial

May 5, 2017
By Omar Ford

Outset brings in $76.5M to expand market penetration for all-in-one dialysis device

May 4, 2017
By Omar Ford

Genome company Wuxi Nextcode backs up 'big data' platform with $75M series B round

May 3, 2017
By Omar Ford

Health Beacons receives U.S. FDA approval for Localizer breast lesion localization system

May 2, 2017
By Omar Ford

Epic Sciences in $40M series D round to further develop liquid biopsy tests

May 1, 2017
By Omar Ford
Epic Sciences Inc. raised $40 million in a series D round, proving investors still have strong interest in the 9-year-old liquid biopsy specialist. The San Diego-based company has taken in about $85 million since it spun out of the Scripps Research Institute in 2008. Its most recent round was led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health Inc., Pagoda Investment, Reach Tone Ltd., RMI Partners, Sabby Capital and VI Ventures also participated in the series D financing. "As Epic has continued to grow and evolve, we see this financing round as a...
Read More

Epic Sciences in $40M series D round to further develop liquid biopsy tests

May 1, 2017
By Omar Ford
Epic Sciences Inc. raised $40 million in a series D round, proving investors still have strong interest in the 9-year-old liquid biopsy specialist. The San Diego-based company has taken in about $85 million since it spun out of the Scripps Research Institute in 2008. Its most recent round was led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health Inc., Pagoda Investment, Reach Tone Ltd., RMI Partners, Sabby Capital and VI Ventures also participated in the series D financing.
Read More

Collaboration is key to innovation in growing digital health care market

April 28, 2017
By Omar Ford
ATLANTA – The digital health market is growing. Taking in about $76.7 billion in 2015, the burgeoning space is sustained through partnerships. However, some smaller med-tech companies often have difficulties partnering with larger companies to foster innovation in the digital health market. Panelists at the Southeastern Medical Device Association (SEMDA) shared some insight on how start ups can get the attention of larger firms and forge a path in digital health. Panelist Omer Inan, an assistant professor of electrical and computer engineering at the Georgia Institute of Technology, said that traditionally the model in academia...
Read More

Collaboration is key to innovation in growing digital health care market

April 28, 2017
By Omar Ford
ATLANTA – The digital health market is growing. Taking in about $76.7 billion in 2015, the burgeoning space is sustained through partnerships. However, some smaller med-tech companies often have difficulties partnering with larger companies to foster innovation in the digital health market. Panelists at the Southeastern Medical Device Association (SEMDA) shared some insight on how start ups can get the attention of larger firms and forge a path in digital health.
Read More

Device hacking, cybersecurity becoming growing concerns for med-tech companies

April 27, 2017
By Omar Ford
ATLANTA – Cybersecurity threats are becoming increasingly prevalent in the med-tech industry. Large companies are not immune to these attacks and are in some cases more of a target than smaller firms. Earlier this month Abbott Laboratories Inc. received an FDA warning letter, citing vulnerabilities with its pacemakers. (See Medical Device Daily, April 17, 2017.) The Abbott Park, Ill.-based company was brought up as an example of the growing threat of cybersecurity breaches during a panel at the Southeastern Medical Device Association's (SEMDA) annual meeting, Wednesday. Panelists presented data from BBR Services that showed 56...
Read More
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing